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Abstract
Nucleos(t)ide analogue (NUC) resistance is an important clinical risk resulting from long-term therapy in chronic hepatitis B (CHB)
management. Discontinuation of NUCs is a feasible strategy to reduce resistance. We aimed to observe the outcomes after NUC
withdrawal in HBeAg-positive CHB patients. A total of 97 patients (11 patients with HBsAg loss and 86 patients with sustained HBeAg
seroconversion) were enrolled. HBV DNA levels and alanine aminotransferase (ALT) levels were monitored regularly after discontinuation.
Relapse was deﬁned as HBV DNA levels >2000 IU/mL in at least two determinations more than 4 weeks apart. HBeAg seroconversion was
achieved within 48 weeks (interquartile range (IQR), 24–72 weeks). The time on consolidation therapy was 96 weeks (IQR, 84–
144 weeks). No relapses occurred for HBsAg loss patients. Evidence of relapse was observed in 9.3% of HBeAg seroconversion patients. All
relapse cases occurred within 48 weeks after discontinuation. The time to relapse was 33  15 weeks. Elevation of HBV DNA and ALT
levels over baseline were only observed in 12.5% of relapse patients. There were no signiﬁcant differences in baseline characteristics (sex,
HBV genotype, age or ALT levels) or time on consolidation therapy between patients with relapse or sustained response. NUC
discontinuation in HBeAg-positive CHB patients is feasible after achieving HBeAg seroconversion at a minimum of 24 weeks. There is
further beneﬁt to prolonging the time on consolidation therapy to reduce relapse. More than 48 weeks of sustained response is a predictive
marker for long-term sustained response.
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Introduction
About 350–400 million people worldwide live with chronic
hepatitis B virus (HBV) infection. Approximately 25% of adults
with chronic HBV infection since childhood later die from
end-stage liver disease [1]. Therefore, the goal of chronic
hepatitis B (CHB) therapy is to achieve sustained suppression
of HBV replication. Nucleos(t)ide analogues (NUCs), including
lamivudine, adefovir, entecavir, telbivudine and tenofovir, are
generally administered for a long duration, as long as 5–6 years
or more, until speciﬁc endpoints are achieved, even though
HBV DNA levels can be suppressed until they are undetect-
able in a much shorter period of time [2].
Chronic hepatitis B may present either as hepatitis B e
antigen (HBeAg) positive or HBeAg negative. HBeAg-positive
CHB is characteristic of immune activation [2]. The ideal
endpoint of therapy is sustained loss of hepatitis B surface
antigen (HBsAg) with or without seroconversion to anti-HBs.
However, the annual rate of HBsAg loss is only 0.5–2.3% [3–6],
whilst loss of HBsAg rates after 1 year were 1% with
lamivudine, 0 with adefovir, 2% with entecavir, 0 with
telbivudine and 3% with tenofovir. Durable HBeAg serocon-
version is a satisfactory endpoint because of its association
with improved prognosis. HBeAg seroconversion rates are c.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE VIROLOGY
Open access under CC BY-NC-ND license.
20% for NUCs, increase with continued NUC treatment and
are affected if resistance occurs [2]. Viral relapse and
exacerbations of hepatitis may occur following discontinuation
of NUC therapy, even for patients who develop HBeAg
seroconversion [1]. Therefore, the decision to continue
therapy after achieving the satisfactory endpoint is a dilemma
faced by both physicians and patients. Continuing with NUC
therapy can reduce the rate of relapse, but unfortunately it can
also lead to resistance or virological breakthrough [7].
Available data based on the long-term outcomes following
NUC withdrawal in HBeAg-positive CHB patients are insuf-
ﬁcient. Hence, we designed this retrospective study, based on
10 years of data on NUC therapy in HBeAg-positive CHB
patients, to observe the long-term outcomes of therapy
discontinuation once ideal or satisfactory endpoints were
achieved.
Patients and Methods
Patients
A total of 97 HBeAg-positive CHB patients (86 with HBeAg
seroconversion and 11 with HBsAg loss), presenting for
treatment at Southwest Hospital from 2002 to 2008, were
included in the current study. The patients who started on one
antiviral agent, such as lamivudine, and switched to another
agent, such as entecavir, because they did not have a good
response were classiﬁed by the last drug used. Patients were
evaluated at least once every 3 months after discontinuation
for alanine aminotransferase (ALT), HBV markers and HBV
DNA levels. Clinical data were collected, monitored and
entered into a database. The outcomes, including sustained
response and relapse, were evaluated during long-term
follow-up for at least 48 weeks. Data were collected during
follow-up appointments through to 1 January 2013.
This analysis was conducted using anonymized data, collected
as part of routine patient care. No additional investigations were
performed. Therefore, no prior informed consent from the
patients was required. The study protocol conformed to the
ethical guidelines of the 1975Declaration ofHelsinki as reﬂected
in a priori approval by the ethics committee of Southwest
Hospital, which waived the need for informed consent.
Inclusion and exclusion criteria
Criteria for inclusion included: presence of serum HBsAg for
at least 6 months; positive for HBeAg; active CHB; and serum
HBV DNA levels >20 000 IU/mL, as measured by Lightcycle
polymerase chain reaction (PCR) assay (lower limit of
detection, 200 IU/mL; Roche Molecular Diagnostics, Basel,
Switzerland). An active CHB was deﬁned by a single serum
ALT level more than 2.0 times the upper limit of normal (ULN,
40 U/L) or at least two determinations 4 weeks apart of ALT
levels 1.0–2.0 9 ULN.
Criteria for exclusion included: coexisting serious medical
or psychiatric illness; organ or bone marrow transplantation;
recent therapy with systemic corticosteroids, immunosup-
pressants or chemotherapeutic agents; a serum alpha-fetopro-
tein level of at least 50 ng/mL; liver disease that was not due to
hepatitis B; and seropositivity for human immunodeﬁciency
virus or hepatitis C or D virus.
Deﬁnitions of therapy time and endpoints
The time to achievingHBeAg seroconversion orHBsAg losswas
deﬁned as from the commencement of treatment (new agent
for switched patients) to the attainment of HBeAg seroconver-
sion or loss of HBsAg. The time on consolidation therapy
was deﬁned from the time of achieving HBeAg serocon-
version or HBsAg loss to the discontinuation of therapy.
In this study, two endpoints were considered: the ideal and
the satisfactory. The ideal endpoint was sustained off-therapy
HBsAg loss with or even without anti-HBs seroconversion.
The satisfactory endpoint was sustained HBeAg seroconver-
sion and biochemical response for at least 24 weeks.
Deﬁnitions of outcomes after discontinuation
Outcomes after discontinuation were either ‘sustained
response’ or ‘virological relapse’. Sustained response was
deﬁned as a sustained off-therapy serological, virological and
biochemical response. Virological relapse was deﬁned as
off-therapy HBV DNA levels >2000 IU/mL in at least two
determinations more than 4 weeks apart.
Serological assays
Routine biochemical tests were performed using automated
techniques. HBsAg, antibody to HBsAg, HBeAg, antibody to
HBeAg and antibody to hepatitis B core antigen were detected
by ELISA (KHB, Shanghai, China) or electrochemiluminescence
(Architect; Abbott Laboratories, Abbott Park, IL, USA).
Antibodies to hepatitis C virus, hepatitis D virus and human
immunodeﬁciency virus were detected by routine, commer-
cially available enzyme immunoassays (KHB). Alpha-fetopro-
tein levels were detected by routine, commercially available
colorimetric assay (KHB). The HBV genotypes were deter-
mined using an HBV gene type PCR ﬂuorescence kit (Fosun,
Shanghai, China).
Statistical methods
Continuous variables were expressed as mean  SD for
normal distributions or median and interquartile range (IQR)
for abnormal distributions. Pearson’s chi-squared tests, Krus-
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kal–Wallis tests, Student’s t-tests, analyses of variance, the
Kaplan–Meier method and log-rank tests were carried out as
appropriate. All tests for signiﬁcance and resulting p values
were two-sided, with a level of signiﬁcance of 0.05. The
statistical software used for this analysis was SPSS 18.0.
Results
Baseline demographic and clinical characteristics
Baseline demographic and clinical characteristics of the
patients are shown in Table 1. There were no signiﬁcant
differences in age, sex, ALT levels or HBV DNA levels at
baseline between patient’s with genotype B and genotype C.
Baseline demographic and clinical characteristics of patient’s
prescribed lamivudine, adefovir, entecavir and telbivudine are
shown in Table 2.
Time of therapy
The time to achieving HBeAg seroconversion and HBsAg loss
was 48 weeks (IQR, 24–72 weeks) and 96 weeks (IQR, 84–
144 weeks), respectively. The time on consolidation therapy
was 96 weeks (IQR, 48–150 weeks). The total length of
therapy was 148 weeks (IQR, 118–201 weeks). The time to
achieving HBeAg seroconversion with lamivudine was
60 weeks (IQR, 30–72 weeks); with adefovir it was 36 weeks
(IQR, 24–72 weeks); with entecavir it was 72 weeks (IQR, 48–
105 weeks); and with telbivudine it was 48 weeks (IQR, 30–
72 weeks). The length of consolidation therapy was
120 weeks (IQR, 51–200 weeks) with lamivudine, 108 weeks
(IQR, 96–144 weeks) with adefovir, 72 weeks (IQR, 48–
105 weeks) with entecavir and 60 weeks (IQR, 24–96 weeks)
with telbivudine.
Long-term outcomes after therapy discontinuation
None of the 11 patients with HBsAg loss relapsed after
127  38 weeks. Therefore, the long-term outcomes after
therapy discontinuation were evaluated for patients who had
undergone HBeAg seroconversion.
Of the 86 patients who experienced HBeAg seroconver-
sion, 9.3% (8/86) relapsed, whilst a sustained response was
observed for 90.7% (78/86). The time of follow-up after
therapy discontinuation for the sustained response patients
was 138  55 weeks. The proportion of relapses after the
withdrawal of lamivudine, adefovir, entecavir and telbivudine
was 12.0% (3/25), 6.9% (2/29), 12.5% (2/16) and 6.3% (1/16),
respectively.
The safety of relapse was investigated by comparing ALT
and HBV DNA levels at baseline and at the time of relapse.
Only 12.5% (1/8) of relapse patients had ALT and HBV DNA
levels greater than baseline levels at the time of relapse.
Fulminant hepatitis was not observed for any relapse patient.
Baseline and relapse levels of ALT and HBV DNA, as well as
treatment strategy after relapse, for all relapse patients are
presented in Table 3.
Characteristics of patients with relapse
The baseline characteristics and therapy time of all patients
were analysed in an attempt to identify features common to all
relapse patients. All relapse cases occurred within 48 weeks
(33  15 weeks) after therapy discontinuation. No signiﬁcant
differences were noted between the sustained response and
TABLE 1. Baseline demographic and clinical characteristics
of patients
Characteristic Genotype B Genotype C p Value
Number (%) 45 (46.4) 52 (53.6)
Male, no. (%) 26 (57.8) 27 (51.9) 0.564
Age (mean  SD), year 25  8 26  7 0.476
<20 15 11
20–29 14 23
>29 16 18
ALT [Median
(IQR)] – ULN
3.3 (2.0–6.7) 4.2 (2.9–7.8) 0.163
<2 9 ULN 11 7
(2–5) 9 ULN 19 21
>5 9 ULN 15 24
HBV DNA
(mean  SD) –
log10 IU/mL
6.6  1.1 6.4  1.1 0.413
TABLE 2. Baseline demographic
and clinical characteristics of NUC
discontinuation for patients treated
with lamivudine, adefovir, entecavir
and telbivudine
Characteristic LAM ADV ETV LDT
Number (%) 28 (28.9) 35 (36.1)a 16 (16.5)b 18 (18.6)
Age (mean  SD), year 26  7 27  7 23  7 25  9
<20 7 7 7 5
20–29 10 14 5 8
>29 11 14 4 5
Male, no. (%) 14 (50.0) 21 (60.0) 11 (68.8) 7 (38.9)
ALT [Median (IQR)] – ULN 3.6 (2.4–7.1) 5.0 (2.6–8.1) 3.3 (2.0–6.8) 3.3 (1.8–6.6)
HBV DNA – log10 IU/mL 7.0  0.8 6.3  1.2 6.4  1.0 6.3  0.9
HBsAg loss, no. (%) 3 (10.7) 6 (17.1) 0 2 (11.1)
LAM, lamivudine; ADV, adefovir; ETV, entecavir; LDT, telbivudine.
aTwo patients switched from LAM.
bOne patient switched from ADV.
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the relapse patients for time to HBeAg seroconversion, length
of consolidation therapy, baseline HBV DNA levels, baseline
ALT levels, baseline age, sex or genotype (Table 4). Notably,
all three patients who switched NUC did not relapse.
Cumulative sustained response rate by survival analysis
To analyse the inﬂuence of multiple factors, we plotted survival
functions between cumulative rate of sustained response and
time of sustained response after NUC discontinuation. The
cumulative rate of sustained response was 91.8%. Although
this analysis was performed using multiple factors, there were
no signiﬁcant differences in the cumulative rate of sustained
response when comparing sex, age, baseline ALT, NUCs or
genotype (Fig. 1).
Discussion
Although the use of NUCs has greatly improved the manage-
ment of CHB, drug resistance still remains an important clinical
risk resulting from long-term therapy. Discontinuation of
NUCs at the appropriate time is a desirable strategy to reduce
the number of drug-resistant cases. However, the time-point
for NUC withdrawal has not been fully agreed. We used a
cohort study, spanning 10 years, to investigate the long-term
outcomes of NUC withdrawal in 97 HBeAg-positive CHB
patients who had achieved HBsAg loss or HBeAg serocon-
version.
In the current study, relapse was not observed (minimum
96 weeks follow-up) for patients who had achieved HBsAg
loss. In similar studies on patients with HBsAg loss, relapse did
not occur during the follow-up period, irrespective of whether
the patient was HBeAg positive or HBeAg negative [8–12].
These results indicate that HBsAg loss is the preferred
endpoint for therapy discontinuation. In another study by
Tseng et al. [13], prognosis after spontaneous HBsAg loss was
good provided cirrhosis did not emerge before HBsAg loss.
This result implies that HBsAg loss, therapy-induced or
spontaneous, may be an ideal outcome for HBeAg-positive
CHB patients.
Despite the rapid suppression of HBV DNA replication for
HBeAg-positive patients, the proportion of HBeAg serocon-
version remains <20% [1,2]. Generally, HBeAg seroconversion
is based on the recovery of immunity to anti-HBV. Durable
HBeAg seroconversion is considered a satisfactory endpoint
because of its reported association with improved prognosis.
However, relapse was observed in 10–40% of patients after
HBeAg seroconversion and NUC withdrawal [1]. In the
current study, the proportion of relapses following HBeAg
seroconversion and NUC withdrawal was 9.3%. Of the 71
patients who relapsed in a study by Yeh et al. [14], 7.0% had
reappearance of HBeAg and 19.7% had HBeAg-negative
hepatitis after lamivudine withdrawal. Cumulative relapse rate
(%) for patients administered lamivudine achieved HBeAg
seroconversion was 23.4% (12 months), 25.0% (24 months),
25.0% (36 months), and 29.4% (48 months), respectively [15].
Chaung et al. [12] reported that 90% of patients who
discontinued therapy once HBeAg seroconversion and com-
plete viral suppression was achieved experienced recurrent
viraemia. The authors therefore suggested that HBeAg sero-
conversion may not be a durable treatment endpoint for many
patients [12]. These results imply that there is still a risk of
relapse following NUC withdrawal despite attainment and
maintenance of HBeAg seroconversion. Differences in rates of
relapse may be associated with differences in the relapse
standard used.
How to forecast relapse or sustained response following
NUC discontinuation is a hot topic in the management of CHB
patients. In the current study, no signiﬁcant differences in
cumulative sustained response rates among sex, baseline age,
baseline ALT levels or genotype were found. These results
TABLE 3. Baseline and relapse levels of ALT and HBV DNA
in patients with relapse
No. NUCs
HBV DNA – log10
IU/mL ALT – 3 ULN
RetreatBaseline Relapse Baseline Relapse
1 LAM 4.34 5.70 11.35 5.83 ETV
2 LAM 6.36 3.37 14.40 0.43 ETV
3 LAM 7.89 6.38 2.25 3.63 ETV
4 LDT 6.83 6.68 20.78 1.95 ETV
5 ETV 6.77 4.04 3.93 0.78 ETV
6 ETV 5.68 3.47 1.60 0.58 ETV
7 ADV 6.29 3.56 6.18 0.33 ETV
8 ADV 5.11 3.31 1.65 0.75 ETV
LAM, lamivudine; ADV, adefovir; ETV, entecavir.
TABLE 4. Baseline characteristics and therapy time of
relapse and sustained response for patients after NUC
discontinuation
Characteristic
SR
(n = 78)
Relapse
(n = 8)
p
Value
HBV DNA –
log10 IU/mL
6.5  1.1 6.5  0.8 0.888
ALT – 9 ULN 3.9 (2.5–7.0) 5.1 (1.8–13.6) 0.525
Age, years 25  8 27  4 0.249
Male, no. (%) 48 (53.9) 5 (62.5) 0.725a
Time to achieving
HBeAg seroconversion,
weeks
48 (24–72) 64 (24–96) 0.451
Consolidation
therapy, weeks
72 (48–147) 108 (30–138) 0. 984
Genotype B, no. (%) 43 (48.3) 2 (25.0) 0.279a
SR, sustained response.
aTwo cells (50.0%) have an expected count <5 with Pearson’s chi-squared tests.
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highlight the inability of current routine clinical indicators to
forecast relapse for HBeAg-positive CHB patients, and are in
direct contrast to the work of others. Yeh et al. [14]
demonstrated that pre-therapeutic HBV DNA levels were
the only predictor for time to relapse. Pan et al. [16] showed
that age at being off therapy, baseline ALT and the different
time periods for prolonged consolidation therapy were
associated with the relapse of HBV after being off therapy.
On the one hand, the smaller number of relapse cases may
have introduced statistical error; on the other hand, according
to our data, age may be the greatest predictor of relapse or
sustained response. It appears that the shorter the
immune-tolerant phase, the greater the potential for achieving
a sustained response after discontinuation of NUCs. Accord-
ing to the natural history of CHB, the immune reactive phase is
more frequently reached in subjects infected during adulthood
[2]. Collectively, this suggests that the immune response to
anti-HBV is the basis for HBeAg seroconversion and for the
sustained response. Although all three patients who switched
NUC treatments did not suffer relapse, statistical analysis was
not undertaken because of the small sample size.
Theoretically, in HBeAg-positive patients who achieved
sustained response after discontinuation, there must be some
characteristics different from the relapse patients. Generally,
immunity to anti-HBV is regarded as the essential difference.
Although, it has been widely documented that changes in
immune responses [17–19] and gene polymorphism are
associated with HBeAg seroconversion [20–23], there is
currently no appropriate standard or markers to predict the
outcome after NUC withdrawal.
It is worth mentioning that all relapse cases occurred within
48 weeks after discontinuation of NUC therapy. This suggests
that a sustained response persisting for >48 weeks is a
predictive marker for a longer-term sustained response follow-
(a) (b)
(c) (d)
(e) (f)
FIG. 1. Survival functions for the cumulative rate of sustained response and the time of sustained response after NUC discontinuation. The
cumulative rate of sustained response was 91.8% (a). No signiﬁcant difference in the cumulative rate of sustained response was observed for sex (b,
p = 0.620), age (c, p = 0.061), baseline ALT (d, p = 0.632), NUCs (e, p = 0.760) or genotype (f, p = 0.202).
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ing discontinuation of NUCs. Furthermore, despite expecta-
tions that a longer consolidation time would produce greater
sustained responses, no signiﬁcant difference in the time on
consolidation therapy between patients with relapse and
sustained response was observed in the current study. This
suggests that 24 weeks of consolidation therapy is sufﬁcient, and
that prolonging the time on consolidation therapy is of little
beneﬁt in reducing/preventing relapse. A recent study by Pan
et al. [16] showed that the cumulative rate of relapse for
subjects exposed to prolonged consolidation therapy was
signiﬁcantly lower than for a group who met current standards
for cessation of NUC therapy (recommended by the 2005
APASL). These results suggest that consolidation therapy with
NUCs following HBeAg seroconversion should be prolonged
[16]. Such discrepancies between studies may be attributed to
different sampling groups or relapse standards.
Furthermore, elevated ALT and HBV DNA levels over
baseline at relapse were observed for only 12.5% of relapse
patients, and no fulminant hepatitis was noted. In a recent
study of 102 HBeAg-positive patients who underwent lamivu-
dine treatment, the incidence of virological relapse, biochem-
ical breakthrough and hepatitis ﬂare was 45.2%, 52.9% and
12.7%, respectively [24]. These results suggest that discontin-
uation of NUC therapy is safe.
Two limitations in our dataset should be noted. First, the
follow-up time for ten patients with a sustained response was
<96 weeks. Second, the majority of patients were treated with
lamivudine and adefovir, the predominant NUCs prescribed in
China from 2002 to 2008. Therefore, the number of patients
who were treated with telbivudine and entecavir was relatively
few. Although entecavir and tenofovir are the preferred
antiviral drugs widely used in current clinical practice, the
current economic climate ensures lamivudine and adefovir are
still used in China. Based on data from HBeAg-positive CHB
patients treated with NUCs, differences in serum immune
response rates using different drugs were very small [2]. This
suggests that a sustained response depends on individual
immunity to HBV rather than to the NUCs used.
In conclusion, NUC discontinuation is feasible for HBeAg--
positive CHB patients after achieving HBeAg seroconversion
at a minimum of 24 weeks. There is no additional beneﬁt in
prolonging the time of consolidation therapy for reducing
relapse. A sustained response of more than 48 weeks is a
predictive marker for long-term sustained response.
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